SCHEMBL6739679

SCHEMBL6739679

NS(=O)(=O)c1c(F)cc(-c2csc(=O)n2-c2cccnc2)cc1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.35
CA2 P00918 6/20 0.35
CA4 P22748 1/20 0.35
CA7 P43166 1/20 0.35
PTGS2 P35354 4/20 0.35
MAPT P10636 1/20 0.35
CYP1A2 P05177 2/20 0.34
METAP2 P50579 1/20 0.34
CA9 Q16790 5/20 0.34
CA12 O43570 4/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 1/20 0.33
EP300 Q09472 1/20 0.33
KAT2B Q92831 1/20 0.33
DPP4 P27487 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6723429 0.87 CA1 (0.36) CA1CA2CA4CA7PTGS2
SCHEMBL6737335 0.83 CA1 (0.36) CA1CA2CA7PTGS2CA9
SCHEMBL6741323 0.82 PTGS2 (0.35) CA1CA2PTGS2CA9CA12
SCHEMBL6728919 0.82 PTGS2 (0.43) CA1CA2PTGS2MAPTCYP1A2
SCHEMBL6735548 0.81 PTGS2 (0.41) CA1CA2PTGS2CA9CA12
SCHEMBL6740773 0.81 CA1 (0.39) CA1CA2CA4CA7PTGS2
SCHEMBL6721805 0.81 PIK3CD (0.36) PTGS2MAPTCYP1A2METAP2NPC1
SCHEMBL6733052 0.81 CYP11B1 (0.35) CA1CA2CA4CA7PTGS2
SCHEMBL6734798 0.80 CA1 (0.38) CA1CA2CA7PTGS2CA9
SCHEMBL6739922 0.80 CA2 (0.42) CA1CA2PTGS2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CA1 2085/4885CA2 3175/4885CA4 3569/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CA1 2085/4885CA2 3175/4885CA4 3569/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 CA1 2085/4885CA2 3175/4885CA4 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.